These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19174038)

  • 1. [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
    Hokland P; Ommen HB; Nyvold CG; Stentoft J; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
    Ugeskr Laeger; 2009 Jan; 171(4):232-5. PubMed ID: 19174038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
    Bartley PA; Ross DM; Latham S; Martin-Harris MH; Budgen B; Wilczek V; Branford S; Hughes TP; Morley AA
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
    Ou J; Vergilio JA; Bagg A
    Am J Hematol; 2008 Apr; 83(4):296-302. PubMed ID: 17957805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.
    Calabrese G; Fantasia D; Di Gianfilippo R; Stuppia L; Di Lorenzo R; Palka G
    Haematologica; 2006 Jul; 91(7):994-5. PubMed ID: 16818290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
    Menif S; Zarrouki S; Jeddi R; ben Alaya N; Ali ZB; Ben Abid H; Hdeiji S; Elloumi M; Khlif A; Meddeb B; Dellagi K
    Pathol Biol (Paris); 2009 Jul; 57(5):388-91. PubMed ID: 18387753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 8. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
    Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and monitoring of minimal residual disease by quantitative real-time PCR.
    Schüler F; Dölken G
    Clin Chim Acta; 2006 Jan; 363(1-2):147-56. PubMed ID: 16154122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
    Tefferi A; Kantarjian H
    Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
    [No Abstract]   [Full Text] [Related]  

  • 11. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The detection and significance of minimal residual disease in chronic myeloid leukemia.
    Radich JP
    Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
    Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
    Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
    Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
    Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
    Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
    Tefferi A; Dewald GW; Litzow ML; Cortes J; Mauro MJ; Talpaz M; Kantarjian HM
    Mayo Clin Proc; 2005 Mar; 80(3):390-402. PubMed ID: 15757021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.
    Sumi M; Tauchi T; Sashida G; Shoji N; Gotoh A; Itoh Y; Miyazawa K; Kimura Y; Ohyashiki JH; Ohyashiki K
    Clin Lab Haematol; 2005 Dec; 27(6):416-7. PubMed ID: 16307547
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring of minimal residual disease in chronic myeloid leukemia.
    Faderl S; Hochhaus A; Hughes T
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):657-70, ix-x. PubMed ID: 15271398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.